Capital One downgraded GlycoMimetics to Equalweight from Overweight with a 50c price target after the company announced its pivotal Phase 3 trial of uproleselan in patients with relapsed or refractory acute myeloid leukemia, or AML, did not achieve a statistically significant improvement in overall survival, or OS.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLYC: